JIA With Non-Systemic Polyarthritis (≥5 Joints): What to Do When Initial DMARD Therapy Fails
This protocol addresses children with juvenile idiopathic arthritis (JIA) and non-systemic polyarthritis involving five or more joints who have not achieved adequate disease control with first-line DMARD therapy.
Clinical Scenario
This population includes children with JIA and polyarthritis (≥5 joints ever involved), spanning multiple ILAR JIA categories, but excludes those with systemic arthritis or sacroiliitis.
The treatment target is low disease activity (clinical JADAS-10 ≤2.5).
Previous Line Failure
The established first-line approach for this scenario is DMARD monotherapy — specifically methotrexate. An adequate trial spans at least 3 months; if no or minimal response is observed after 6–8 weeks, adjustment may be appropriate.
When first-line DMARD therapy fails to achieve low disease activity (clinical JADAS-10 ≤2.5), escalation to the next structured step is indicated.
Next Step
After DMARD monotherapy falls short of the low disease activity target, the evidence-based approach involves adding a biologic agent to the existing DMARD — a strategy that is specifically recommended over switching to a different DMARD or escalating to triple DMARD therapy. Combination with a DMARD is preferred over biologic monotherapy. The complete protocol specifies which biologic classes apply and the recommended combination framework.
References
DOI: 10.1002/acr.23870
This group includes children with JIA and polyarthritis (≥5 joints ever involved) and may include children from different ILAR JIA categories but excludes children with systemic arthritis or sacroiliitis.
In patients with JIA and polyarthritis and moderate or high disease activity despite DMARD monotherapy, adding a biologic to the original DMARD is conditionally recommended over changing to a second DMARD.
In patients with JIA and polyarthritis and moderate or high disease activity receiving DMARD monotherapy, adding a biologic is conditionally recommended over changing to triple DMARD therapy.
View source ↗